Heartbeam Price Target Announced at $2.00/Share by Maxim Group
Maxim Group Initiates HeartBeam(BEAT.US) With Buy Rating, Announces Target Price $2
HeartBeam Wins U.S. Patent Expanding ECG Device With Acoustic Sensing, Impedance Features For Heart Disease Monitoring
Express News | Heartbeam Awarded New U.S. Patent Expanding Acoustic Sensing and Fluid Monitoring Capabilities of Its Cable-Free Ecg Device
HeartBeam Receives Nasdaq Notice on Minimum Bid Price
HeartBeam (NASDAQ: BEAT) Advances Modern Cardiac Care, Expanding Use of ECG Data Outside of the Hospital
HeartBeam (NASDAQ: BEAT) Completes Enrollment Ahead of Schedule in Heart Attack Detection Pilot Study
HeartBeam Shares Are Trading Higher After the Company Announced Completion of Patient Enrollment in Its ALIGN-ACS Pilot Study Evaluating the HeartBeam System for Heart Attack Detection.
HeartBeam to License 3D ECG Signal Technology to Established Partners to Accelerate Adoption
Express News | Heartbeam - Advancing Toward Heart Attack Detection as Key Platform Expansion
Express News | Heartbeam Announces Strategic Shift to Accelerate Global Adoption of Its Ambulatory Ecg Signal Platform and Leadership Transition
HeartBeam Publishes JACC Study Showing Its Credit Card‐Sized ECG Device Can Predict Heart Attack Risk In Chest Pain Patients
HeartBeam (NASDAQ: BEAT) Aims to Close Critical Gap in Early Cardiac Detection
H.C. Wainwright Maintains HeartBeam(BEAT.US) With Buy Rating, Cuts Target Price to $2.5
Express News | Heartbeam, Inc. : H.c. Wainwright Cuts Target Price to $2.5 From $5.5
Benchmark Co. Maintains HeartBeam(BEAT.US) With Buy Rating, Cuts Target Price to $5
HeartBeam Earnings Call: Funding Extends Runway, Trials Advance
HeartBeam (NASDAQ: BEAT) Advances Commercial Launch, Reports First-Quarter 2026 Results
HeartBeam, Inc. (BEAT) Q1 2026 Earnings Call Transcript Summary
HeartBeam Q1 2026 Earnings Call: Complete Transcript